Volume 6, Issue 2 pp. 92-97
Research Article
Full Access

No germline TP53 mutations detected in familial and bilateral testicular cancer

Ketil Heimdal

Ketil Heimdal

Department of Genetics. Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

Search for more papers by this author
Ragnhild A. Lothe

Ragnhild A. Lothe

Department of Genetics. Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

Search for more papers by this author
Sigrid Lystad

Sigrid Lystad

Department of Genetics. Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

Search for more papers by this author
Ruth Holm

Ruth Holm

Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway

Search for more papers by this author
Sophie D. Fosså

Sophie D. Fosså

Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway

Search for more papers by this author
Prof. Anne-Lise Børresen

Corresponding Author

Prof. Anne-Lise Børresen

Department of Genetics. Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, N-0310 Oslo, NorwaySearch for more papers by this author
First published: February 1993
Citations: 60

Abstract

Mutations in the TP53 gene are considered to be among the most common genetic alterations in human cancers. Both somatic and germline mutations have been found. Using potymerase chain reaction (PCR), constant denaturant gel electrophoresis (CDGE), and denaturing gradient gel electrophoresis (DGGE), we have examined 32 patients with bilateral and familial germ cell tumors (GCT) and two patients with sporadic GCT for germline mutations within the conserved regions of the gene. In addition, 15 tumors were screened for somatic mutations and analyzed for loss of heterozygocity (LOH) at the TP53 locus. Twelve tumors were analyzed for expression of TP53 via immunohistochemistry. Neither germline nor somatic TP53 mutations were deteeted. LOH was observed in one of five informative cases. No tumors showed increased expression of TP53 protein. These results indicate that alterations in the TP53 gene are not important for the predisposition to and development of GCT. © 1993 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.